000			02346 a2200625 4500
005			20250515110532.0
264		0	_c20080416
008			200804s 0 0 eng d
022			_a1569-8041
024	7		_a10.1093/annonc/mdm607 _2doi
040			_aNLM _beng _cNLM
100	1		_aTol, J
245	0	0	_aA randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. _h[electronic resource]
260			_bAnnals of oncology : official journal of the European Society for Medical Oncology _cApr 2008
300			_a734-8 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntibodies, Monoclonal _xadministration & dosage
650	0	4	_aAntibodies, Monoclonal, Humanized
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects
650	0	4	_aBevacizumab
650	0	4	_aCapecitabine
650	0	4	_aCarcinoma _xdrug therapy
650	0	4	_aCetuximab
650	0	4	_aColorectal Neoplasms _xdrug therapy
650	0	4	_aDeoxycytidine _xadministration & dosage
650	0	4	_aDisease-Free Survival
650	0	4	_aDrug Eruptions _xetiology
650	0	4	_aFemale
650	0	4	_aFluorouracil _xadministration & dosage
650	0	4	_aHumans
650	0	4	_aIncidence
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aNetherlands
650	0	4	_aOrganoplatinum Compounds _xadministration & dosage
650	0	4	_aOxaliplatin
650	0	4	_aSeverity of Illness Index
650	0	4	_aSurvival Analysis
650	0	4	_aTreatment Outcome
700	1		_aKoopman, M
700	1		_aRodenburg, C J
700	1		_aCats, A
700	1		_aCreemers, G J
700	1		_aSchrama, J G
700	1		_aErdkamp, F L G
700	1		_aVos, A H
700	1		_aMol, L
700	1		_aAntonini, N F
700	1		_aPunt, C J A
773	0		_tAnnals of oncology : official journal of the European Society for Medical Oncology _gvol. 19 _gno. 4 _gp. 734-8
856	4	0	_uhttps://doi.org/10.1093/annonc/mdm607 _zAvailable from publisher's website
999			_c17777790 _d17777790